Human papillomavirus type 18 protein E7 (HPV18 E7) (HPV18 E7)

Human papillomavirus type 18 protein E7 (HPV18 E7) is a critical oncoprotein encoded by the high-risk HPV18 virus, which is a primary causative agent of cervical, anogenital, and oropharyngeal cancers (UniProt P06788; NIH/NCI). The protein's primary mechanism of oncogenesis involves binding to the retinoblastoma protein (pRb) and its family members (p107 and p130), leading to their degradation via the ubiquitin-proteasome pathway (Virology, 2013, PMID: 23973178). This degradation releases E2F transcription factors, which drive the host cell into the S-phase of the cell cycle, promoting uncontrolled proliferation and genomic instability (PubMed, PMID: 31533979). Additionally, HPV18 E7 interacts with various other cellular factors to inhibit apoptosis and subvert the host immune response, facilitating persistent viral infection (UniProt P06788). In clinical development, E7 is a major target for therapeutic vaccines and immunotherapies because it is constitutively expressed in HPV-transformed cells but absent in normal tissues (Inovio Pharmaceuticals; ClinicalTrials.gov). Current therapeutic strategies include DNA vaccines like VGX-3100 and viral vector-based platforms designed to elicit a robust T-cell response against E7-expressing tumor cells (ClinicalTrials.gov, NCT02849496).

Other names

E7 proteinHPV-18 E7Protein E7Early protein E7VE7_HPV18

Therapeutic vaccines targeting HPV18 E7 work by inducing a robust CD8+ T-cell response that recognizes E7 peptides presented on MHC class I molecules of infected or malignant cells, leading to targeted cell lysis (ClinicalTrials.gov, NCT02849496). At the molecular level, E7 acts by binding the LXCXE motif to the pocket domain of pRb, recruiting the Cullin-2 ubiquitin ligase complex to trigger pRb degradation (UniProt P06788; Virology, 2013, PMID: 23973178).